The Expression and Therapeutic Potential of Checkpoint Kinase 2 in Laryngeal Squamous Cell Carcinoma

References

• CossuAM, MoscaL, ZappavignaS, et al. Long non-coding RNAs as important biomarkers in laryngeal cancer and other head and neck tumours. Int J Mol Sci. 2019;20(14):3444. doi:10.3390/ijms20143444
   PubMed Web of Science ®Google Scholar
• BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• SteuerCE, El-DeiryM, ParksJR, HigginsKA, SabaNF. An update on larynx cancer. CA Cancer J Clin. 2017;67(1):31–50. doi:10.3322/caac.2138627898173
   PubMed Web of Science ®Google Scholar
• KuperH, BoffettaP, AdamiHO. Tobacco use and cancer causation: association by tumour type. J Intern Med. 2002;252(3):206–224. doi:10.1046/j.1365-2796.2002.01022.x12270001
   PubMed Web of Science ®Google Scholar
• BoffettaP, HashibeM. Alcohol and cancer. Lancet Oncol. 2006;7(2):149–156. doi:10.1016/S1470-2045(06)70577-016455479
   PubMed Web of Science ®Google Scholar
• GaravelloW, LucenteforteE, BosettiC, et al. Diet diversity and the risk of laryngeal cancer: a case-control study from Italy and Switzerland. Oral Oncol. 2009;45(1):85–89. doi:10.1016/j.oraloncology.2008.02.01118487075
   PubMed Web of Science ®Google Scholar
• KobayashiK, HisamatsuK, SuzuiN, HaraA, TomitaH, MiyazakiT. A review of HPV-related head and neck cancer. J Clin Med. 2018;7(9):241. doi:10.3390/jcm7090241
   PubMed Web of Science ®Google Scholar
• PommierY, WeinsteinJN, AladjemMI, KohnKW. Chk2 molecular interaction map and rationale for Chk2 inhibitors. Clin Cancer Res. 2006;12(9):2657–2661. doi:10.1158/1078-0432.CCR-06-074316675556
   PubMed Web of Science ®Google Scholar
• ZanniniL, DeliaD, BuscemiG. CHK2 kinase in the DNA damage response and beyond. J Mol Cell Biol. 2014;6(6):442–457. doi:10.1093/jmcb/mju04525404613
   PubMed Web of Science ®Google Scholar
• TanY, RaychaudhuriP, CostaRH. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol. 2007;27(3):1007–1016. doi:10.1128/MCB.01068-0617101782
   PubMed Web of Science ®Google Scholar
• AntoniL, SodhaN, CollinsI, GarrettMD. CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nat Rev Cancer. 2007;7(12):925–936. doi:10.1038/nrc225118004398
   PubMed Web of Science ®Google Scholar
• SunX, LiuB, WangJ, LiJ, JiWY. Inhibition of p21-activated kinase 4 expression suppresses the proliferation of Hep-2 laryngeal carcinoma cells via activation of the ATM/Chk1/2/p53 pathway. Int J Oncol. 2013;42(2):683–689. doi:10.3892/ijo.2012.171823229348
   PubMed Web of Science ®Google Scholar
• CybulskiC, GorskiB, HuzarskiT, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004;75(6):1131–1135. doi:10.1086/42640315492928
   PubMed Web of Science ®Google Scholar
• BartkovaJ, GuldbergP, GronbaekK, et al. Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer. Oncogene. 2004;23(52):8545–8551. doi:10.1038/sj.onc.120787815361851
   PubMed Web of Science ®Google Scholar
• CarloniV, LulliM, MadiaiS, et al. CHK2 overexpression and mislocalisation within mitotic structures enhances chromosomal instability and hepatocellular carcinoma progression. Gut. 2018;67(2):348–361. doi:10.1136/gutjnl-2016-31311428360097
   PubMed Web of Science ®Google Scholar
• YoonAJ, ShenJ, SantellaRM, ZegarelliDJ, ChenR, WeinsteinIB. Activated checkpoint kinase 2 expression and risk for oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2768–2772. doi:10.1158/1055-9965.EPI-07-065918086786
   PubMed Web of Science ®Google Scholar
• ChouSJ, AlawiF. Expression of DNA damage response biomarkers during oral carcinogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111(3):346–353. doi:10.1016/j.tripleo.2010.10.03221310354
   PubMed Web of Science ®Google Scholar
• CardosoSCS, DuarteA, de AlmeidaLY, LeónJE, Ribeiro-SilvaA. Immunohistochemistry analysis of checkpoint kinase 2 in oral squamous cell carcinoma. Appl Cancer Res. 2020;40(1):1–6. doi:10.1186/s41241-020-00085-y
   Google Scholar
• TangZ, LiC, KangB, GaoG, LiC, ZhangZ. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx24728407145
   PubMed Web of Science ®Google Scholar
• VasaikarSV, StraubP, WangJ, ZhangB. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–D963. doi:10.1093/nar/gkx109029136207
   PubMed Web of Science ®Google Scholar
• ZhouY, ZhouB, PacheL, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523. doi:10.1038/s41467-019-09234-630944313
   PubMed Web of Science ®Google Scholar
• Fatehi HassanabadA, ChehadeR, BreadnerD, RaphaelJ. Esophageal carcinoma: towards targeted therapies. Cell Oncol. 2019.
   Web of Science ®Google Scholar
• ArientiKL, BrunmarkA, AxeFU, et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005;48(6):1873–1885. doi:10.1021/jm049593515771432
   PubMed Web of Science ®Google Scholar
• WickCC, RezaeeRP, WangT, et al. Use of concurrent chemoradiation in advanced staged (T4) laryngeal cancer. Am J Otolaryngol. 2017;38(1):72–76. doi:10.1016/j.amjoto.2016.10.00127838151
   PubMed Web of Science ®Google Scholar
• LiJ, WilliamsBL, HaireLF, et al. Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell. 2002;9(5):1045–1054. doi:10.1016/S1097-2765(02)00527-012049740
   PubMed Web of Science ®Google Scholar
• BartekJ, LukasJ. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3(5):421–429. doi:10.1016/S1535-6108(03)00110-712781359
   PubMed Web of Science ®Google Scholar
• SunH, WangY, WangZ, MengJ, QiZ, YangG. Aurora-A controls cancer cell radio- and chemoresistance via ATM/Chk2-mediated DNA repair networks. Biochim Biophys Acta. 2014;1843(5):934–944. doi:10.1016/j.bbamcr.2014.01.01924480460
   PubMed Web of Science ®Google Scholar
• WuX, WebsterSR, ChenJ. Characterization of tumor-associated Chk2 mutations. J Biol Chem. 2001;276(4):2971–2974. doi:10.1074/jbc.M00972720011053450
   PubMed Web of Science ®Google Scholar
• BahassiEM, RobbinsSB, YinM, et al. Mice with the CHEK2*1100delC SNP are predisposed to cancer with a strong gender bias. Proc Natl Acad Sci U S A. 2009;106(40):17111–17116. doi:10.1073/pnas.090923710619805189
   PubMed Web of Science ®Google Scholar
• DaiB, ZhaoXF, Mazan-MamczarzK, et al. Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma. Nat Commun. 2011;2:402. doi:10.1038/ncomms140421772273
   PubMed Web of Science ®Google Scholar